Skip to content
Subscriber Only

Endo Works With FDA on Request to Pull Opioid Pain Pill

  • Drug prescribed 50,000 times a month in the U.S., CEO says
  • ‘Little disappointed’ that FDA didn’t collaborate, CEO says

Endo International Plc is working with the U.S. Food and Drug Administration to address the agency’s unprecedented request that it pull the powerful opioid pain medication Opana ER off the market because of potential abuse, Chief Executive Officer Paul Campanelli said.

The FDA asked Endo to stop selling the drug last week, the first time the agency made such a move amid what it calls a public-health crisis. The agency is trying to contain an outbreak of dangerous infections by addicts who abuse drugs like Opana ER that are approved for legitimate pain relief.